Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and DA-EPOCH-R in relapsed/refractory DLBCL and Hodgkin lymphoma
NCT01030900Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2009
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), sponsored by National Cancer Institute. Started Oct 2009; status: completed.
02
Drugs
alemtuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01030900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030900.